Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

BXQ-350

Other · Acts on phosphatidylserine · developed by Bexion Pharmaceuticals

Phase 1/2 Most advanced trial
1 Registered trials

What is BXQ-350?

BXQ-350 is a nanovesicle formulation of synthetic saposin C linked to the phospholipid DOPS. It accumulates in tumor vessels and cells, where saposin C fuses with membranes and activates lysosomal enzymes, raising intracellular ceramide and inducing apoptosis. It is being studied in metastatic colorectal carcinoma and neuropathy.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
SapC-DOPS
Drug type
Other
Targets
phosphatidylserine, beta-glucosidase (GBA1) (secondary target), acid sphingomyelinase (SMPD1) (secondary target), beta-galactosylceramidase (GALC) (secondary target)
Mechanism
Acts on phosphatidylserine
Pathways
ceramide-mediated apoptosis, caspase activation, sphingolipid metabolism, lysosomal lipid degradation
Therapy area
Oncology
Developer
Bexion Pharmaceuticals, Inc.
In trials of
ICLR
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
2N62LTC861

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05322590 Phase 1/2 Metastatic Colorectal Carcinoma Active not recruiting ICLR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Metastatic Colorectal CarcinomaNeuropathy

Sources

Updated Nov 15, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.